Literature DB >> 29533500

The burden of hepatitis C virus in Cameroon: Spatial epidemiology and historical perspective.

R Njouom1, I Siffert2, G Texier1,3, G Lachenal4, M C Tejiokem1, J Pépin5, A Fontanet2,6.   

Abstract

Cameroon is thought to have one of the highest prevalences of hepatitis C virus (HCV) infection in the world (4.9% among adults). A marked cohort effect exists in several communities where ≈50% of the elderly are infected. Better assessment of HCV distribution is needed for planning treatment programmes. We tested for HCV antibodies 14 150 capillary blood samples collected during the 2011 Demographic and Health Survey, whose participants were representative of the Cameroonian population aged 15-49 (both genders) and 50-59 years (men only). Historical data on exposure to medical care were collected and factors associated with HCV assessed through logistic regression and geospatial analyses. To estimate prevalence in all persons aged ≥15 years, we used data from the survey for the 15-59 years fraction and modelled a cohort effect for older individuals. The nationwide HCV prevalence was 0.81% for the 15-49 years group, and 2.51% for all individuals aged ≥15 years. Only 0.2% of individuals aged 15-19 were seropositive. Among participants aged 15-44 years, HCV was associated with age, rural residence and, for males, with ritual circumcision. For those aged 45-59 years, HCV was associated with age and access to medical care in the late 1950s. Prevalence of HCV seropositivity in Cameroon is half of previous estimates. Nationwide surveys are essential to rationalize resources allocation. The high prevalence among older cohorts, a colonial legacy, has had little spillover into younger cohorts. HCV-free generations might be attainable in countries not plagued with intravenous drug abuse.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  Cameroon; hepatitis C virus; iatrogenic transmission

Mesh:

Substances:

Year:  2018        PMID: 29533500     DOI: 10.1111/jvh.12894

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  5 in total

1.  Performance evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus in Cameroon.

Authors:  Clavel Landry Kouam Fondjo; Paul Alain Tagnouokam Ngoupo; Laure Ngono; Jean-Christophe Plantier; Richard Njouom
Journal:  BMC Res Notes       Date:  2018-06-05

2.  Achieving a high cure rate with direct-acting antivirals for chronic Hepatitis C virus infection in Cameroon: a multi-clinic demonstration project.

Authors:  Liza Coyer; Oudou Njoya; Richard Njouom; Tatiana Mossus; Mathurin Pierre Kowo; Frida Essomba; Alexander Boers; Roel Coutinho; Pascale Ondoa
Journal:  Trop Med Int Health       Date:  2020-07-05       Impact factor: 2.622

3.  Epidemiologic profile of viral hepatitis B and C in North of Iran: results from PERSIAN Guilan Cohort Study (PGCS).

Authors:  Fariborz Mansour-Ghanaei; Farahnaz Joukar; Mohammadreza Naghipour; Soheil Hassanipour; Sara Yeganeh; Masood Sepehrimanesh; Mohammad Fathalipour
Journal:  BMC Res Notes       Date:  2021-02-10

4.  A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi, suggests a historic mechanism of transmission.

Authors:  Alexander J Stockdale; Benno Kreuels; Isaac T Shawa; James E Meiring; Deus Thindwa; Niza M Silungwe; Karen Chetcuti; Elizabeth Joekes; Maurice Mbewe; Blessings Mbale; Pratiksha Patel; Rabson Kachala; Priyanka D Patel; Jane Malewa; Peter Finch; Chris Davis; Rajiv Shah; Lily Tong; Ana da Silva Filipe; Emma C Thomson; Anna Maria Geretti; Melita A Gordon
Journal:  J Viral Hepat       Date:  2022-02-09       Impact factor: 3.517

Review 5.  Dried Blood Spot Tests for the Diagnosis and Therapeutic Monitoring of HIV and Viral Hepatitis B and C.

Authors:  Edouard Tuaillon; Dramane Kania; Amandine Pisoni; Karine Bollore; Fabien Taieb; Esther Nina Ontsira Ngoyi; Roxane Schaub; Jean-Christophe Plantier; Alain Makinson; Philippe Van de Perre
Journal:  Front Microbiol       Date:  2020-03-09       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.